IMCY-0098 is under clinical development by ImCyse and currently in Phase II for Type 1 Diabetes (Juvenile Diabetes). According to GlobalData, Phase II drugs for Type 1 Diabetes (Juvenile Diabetes) have a 54% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how IMCY-0098’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

IMCY-0098 overview

IMCY-0098 is under development for the prevention of type 1 diabetes. It is administered through subcutaneous route. It is a synthetic peptide that encompasses MHC class II-restricted epitopes flanked with a thioredox motif which induces epitope-specific cytolytic T cells. The drug candidate is developed based on Imotope technology.

ImCyse overview

ImCyse is a pharmaceutical company. The company operates as a clinical-stage biotechnology company that focuses on the development of specific active therapeutics for the treatment of severe chronic diseases. It offers products in the therapeutic areas of type 1 diabetes, allergic diseases, multiple sclerosis, myasthenia gravis, prevention of graft rejection and blocking of immunogenicity to viral vectors. The company works in partnership with public funding bodies and pharmaceutical companies to expand its product portfolio. Its technology platform represents the next generation of therapeutic biologics. ImCyse is headquartered in Liege, Belgium.

For a complete picture of IMCY-0098’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 2 September 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.